Australia. The Adverse Drug Reactions Advisory Committee (ADRAC) in Australia has received 44 adverse event reports associated with rosiglitazone and 28 with pioglitazone. These include 12 reports of hepatic reactions with rosiglitazone and four with pioglitazone, and six reports of cardiac reactions with pioglitazone and 12 with rosiglitazone. The committee states that these drugs should not be used in patients with liver disease or in patients whose cardiac failure limits their physical activity, and that monitoring of liver and cardiac function is required.

Reference:
Australian Adverse Drug Reactions Bulletin 22: 6-7, Apr 2003.